The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites

Minkyu Jung, Hei Cheul Jeung, Sung Sook Lee, Jun Yong Park, Soojung Hong, Soo Hyeon Lee, Sung Hoon Noh, Hyun Cheol Chung, Sun Young Rha

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: This study was carried out to evaluate the clinical significance of ascitic fluid carcinoembryonic antigen (CEA) in advanced gastric cancer patients with ascites. Patients and methods: From November 2001 to February 2008, 119 gastric cancer patients with concurrent ascites who were clinically diagnosed with carcinomatosis, were retrospectively reviewed with regard to ascitic fluid cytology and clinicopathological parameters. Serum CEA (sCEA) and ascitic fluid CEA (aCEA) were measured using a chemiluminescent enzyme immunoassay. Results: The patients' median age was 50 years (range 23-80 years). The median value of aCEA was significantly higher than sCEA [130.5 ng/ml (range 0.2-12.211 ng/ml) vs. 2.1 ng/ml (range 0.02-8.152 ng/ml), p < 0.001]. Sixty-five patients (54.6%) had positive ascitic fluid cytology. The median overall survival of all patients was 3.0 months (95% CI 2.0-4.0 months). The patients with low aCEA (<5 ng/ml) had a significantly longer overall survival compared to patients with high aCEA (≥5 ng/ml) (7.4 months vs. 2.3 months, p = 0.003). However, we found no difference in overall survival according to ascitic fluid cytology (median, 3.0 months vs. 2.5 months, p = 0.530). Multivariate analysis also demonstrated that aCEA levels of more than 5 ng/ml were associated with poor prognosis (HR = 2.88; 95% CI 1.45-5.74; p = 0.003), while sCEA levels were not associated with poor prognosis (HR = 1.15; 95% CI 0.67-2.03; p = 0.622). Conclusion: These results suggest that aCEA levels can be used as a prognostic marker for advanced gastric cancer patients with ascites.

Original languageEnglish
Pages (from-to)517-526
Number of pages10
JournalJournal of cancer research and clinical oncology
Volume136
Issue number4
DOIs
Publication statusPublished - 2010 Apr 1

Fingerprint

Ascitic Fluid
Carcinoembryonic Antigen
Ascites
Stomach Neoplasms
Cell Biology
Survival
Serum
Immunoenzyme Techniques
Multivariate Analysis
Carcinoma

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Jung, Minkyu ; Jeung, Hei Cheul ; Lee, Sung Sook ; Park, Jun Yong ; Hong, Soojung ; Lee, Soo Hyeon ; Noh, Sung Hoon ; Chung, Hyun Cheol ; Rha, Sun Young. / The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. In: Journal of cancer research and clinical oncology. 2010 ; Vol. 136, No. 4. pp. 517-526.
@article{3b384f924f0e4b22967a69e4ece7ee50,
title = "The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites",
abstract = "Background: This study was carried out to evaluate the clinical significance of ascitic fluid carcinoembryonic antigen (CEA) in advanced gastric cancer patients with ascites. Patients and methods: From November 2001 to February 2008, 119 gastric cancer patients with concurrent ascites who were clinically diagnosed with carcinomatosis, were retrospectively reviewed with regard to ascitic fluid cytology and clinicopathological parameters. Serum CEA (sCEA) and ascitic fluid CEA (aCEA) were measured using a chemiluminescent enzyme immunoassay. Results: The patients' median age was 50 years (range 23-80 years). The median value of aCEA was significantly higher than sCEA [130.5 ng/ml (range 0.2-12.211 ng/ml) vs. 2.1 ng/ml (range 0.02-8.152 ng/ml), p < 0.001]. Sixty-five patients (54.6{\%}) had positive ascitic fluid cytology. The median overall survival of all patients was 3.0 months (95{\%} CI 2.0-4.0 months). The patients with low aCEA (<5 ng/ml) had a significantly longer overall survival compared to patients with high aCEA (≥5 ng/ml) (7.4 months vs. 2.3 months, p = 0.003). However, we found no difference in overall survival according to ascitic fluid cytology (median, 3.0 months vs. 2.5 months, p = 0.530). Multivariate analysis also demonstrated that aCEA levels of more than 5 ng/ml were associated with poor prognosis (HR = 2.88; 95{\%} CI 1.45-5.74; p = 0.003), while sCEA levels were not associated with poor prognosis (HR = 1.15; 95{\%} CI 0.67-2.03; p = 0.622). Conclusion: These results suggest that aCEA levels can be used as a prognostic marker for advanced gastric cancer patients with ascites.",
author = "Minkyu Jung and Jeung, {Hei Cheul} and Lee, {Sung Sook} and Park, {Jun Yong} and Soojung Hong and Lee, {Soo Hyeon} and Noh, {Sung Hoon} and Chung, {Hyun Cheol} and Rha, {Sun Young}",
year = "2010",
month = "4",
day = "1",
doi = "10.1007/s00432-009-0684-3",
language = "English",
volume = "136",
pages = "517--526",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "4",

}

The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. / Jung, Minkyu; Jeung, Hei Cheul; Lee, Sung Sook; Park, Jun Yong; Hong, Soojung; Lee, Soo Hyeon; Noh, Sung Hoon; Chung, Hyun Cheol; Rha, Sun Young.

In: Journal of cancer research and clinical oncology, Vol. 136, No. 4, 01.04.2010, p. 517-526.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites

AU - Jung, Minkyu

AU - Jeung, Hei Cheul

AU - Lee, Sung Sook

AU - Park, Jun Yong

AU - Hong, Soojung

AU - Lee, Soo Hyeon

AU - Noh, Sung Hoon

AU - Chung, Hyun Cheol

AU - Rha, Sun Young

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Background: This study was carried out to evaluate the clinical significance of ascitic fluid carcinoembryonic antigen (CEA) in advanced gastric cancer patients with ascites. Patients and methods: From November 2001 to February 2008, 119 gastric cancer patients with concurrent ascites who were clinically diagnosed with carcinomatosis, were retrospectively reviewed with regard to ascitic fluid cytology and clinicopathological parameters. Serum CEA (sCEA) and ascitic fluid CEA (aCEA) were measured using a chemiluminescent enzyme immunoassay. Results: The patients' median age was 50 years (range 23-80 years). The median value of aCEA was significantly higher than sCEA [130.5 ng/ml (range 0.2-12.211 ng/ml) vs. 2.1 ng/ml (range 0.02-8.152 ng/ml), p < 0.001]. Sixty-five patients (54.6%) had positive ascitic fluid cytology. The median overall survival of all patients was 3.0 months (95% CI 2.0-4.0 months). The patients with low aCEA (<5 ng/ml) had a significantly longer overall survival compared to patients with high aCEA (≥5 ng/ml) (7.4 months vs. 2.3 months, p = 0.003). However, we found no difference in overall survival according to ascitic fluid cytology (median, 3.0 months vs. 2.5 months, p = 0.530). Multivariate analysis also demonstrated that aCEA levels of more than 5 ng/ml were associated with poor prognosis (HR = 2.88; 95% CI 1.45-5.74; p = 0.003), while sCEA levels were not associated with poor prognosis (HR = 1.15; 95% CI 0.67-2.03; p = 0.622). Conclusion: These results suggest that aCEA levels can be used as a prognostic marker for advanced gastric cancer patients with ascites.

AB - Background: This study was carried out to evaluate the clinical significance of ascitic fluid carcinoembryonic antigen (CEA) in advanced gastric cancer patients with ascites. Patients and methods: From November 2001 to February 2008, 119 gastric cancer patients with concurrent ascites who were clinically diagnosed with carcinomatosis, were retrospectively reviewed with regard to ascitic fluid cytology and clinicopathological parameters. Serum CEA (sCEA) and ascitic fluid CEA (aCEA) were measured using a chemiluminescent enzyme immunoassay. Results: The patients' median age was 50 years (range 23-80 years). The median value of aCEA was significantly higher than sCEA [130.5 ng/ml (range 0.2-12.211 ng/ml) vs. 2.1 ng/ml (range 0.02-8.152 ng/ml), p < 0.001]. Sixty-five patients (54.6%) had positive ascitic fluid cytology. The median overall survival of all patients was 3.0 months (95% CI 2.0-4.0 months). The patients with low aCEA (<5 ng/ml) had a significantly longer overall survival compared to patients with high aCEA (≥5 ng/ml) (7.4 months vs. 2.3 months, p = 0.003). However, we found no difference in overall survival according to ascitic fluid cytology (median, 3.0 months vs. 2.5 months, p = 0.530). Multivariate analysis also demonstrated that aCEA levels of more than 5 ng/ml were associated with poor prognosis (HR = 2.88; 95% CI 1.45-5.74; p = 0.003), while sCEA levels were not associated with poor prognosis (HR = 1.15; 95% CI 0.67-2.03; p = 0.622). Conclusion: These results suggest that aCEA levels can be used as a prognostic marker for advanced gastric cancer patients with ascites.

UR - http://www.scopus.com/inward/record.url?scp=77949261570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949261570&partnerID=8YFLogxK

U2 - 10.1007/s00432-009-0684-3

DO - 10.1007/s00432-009-0684-3

M3 - Article

C2 - 19774395

AN - SCOPUS:77949261570

VL - 136

SP - 517

EP - 526

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 4

ER -